Morgan Stanley analyst Sean Laaman assumed coverage of Alector (ALEC) with an Underweight rating and a price target of $1.50, down from $3. The firm sees no meaningful catalyst until Q4 of 2025, at which time Alector may have less than one year of cash on the balance sheet, the analyst tells investors. The firm views the latozinemab program as de-risked, but sees challenges translating results with latozinemab in FTD-GRN to AL101 in Alzheimer’s disease, the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Cautious Outlook on Alector: Limited Prospects for Latozinemab and Financial Uncertainty Drive Sell Rating
- Alector’s Earnings Call: Progress Amid Challenges
- Promising Clinical Data and Scientific Rationale Support Alector’s Therapeutic Approach in Neurodegenerative Diseases
- Alector’s 2024 Financial Results and Clinical Advancements
- Alector reports Q4 EPS (2c), consensus (54c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue